KRAS and cancer: This is in line with recent studies showing a stronger potential of the SOS1 inhibitor BI-3406 to limit cancer cell proliferation in NCI-H23 isogenic cells bearing a KRAS mutation in heterozygosis compared with the homozygous counterpart [32], making relevant the evaluation of the wild-type allele contribution upon SOS1 inhibition.